Biocon Limited is an India-based biopharmaceutical company that focuses to treat diabetes, cancer and autoimmune diseases. The Company is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

Company Officers

Kiran Mazumdarshaw
Executive Chairperson of the Board
Siddharth Mittal
Chief Executive Officer, Managing Director, Executive Director
Indranil Sen
Chief Financial Officer
Shreehas Tambe
Deputy Chief Executive Officer
Amitava Saha
Chief Human Resource Officer
Mayank Verma
Compliance Officer, Company Secretary
Sriram A.V.
Head - Quality
Seema Ahuja
Chief Communications Officer
Prasad Deshpand
Head - Supply Chain and Central Engineering
Vijaya Kumar
Head - Operations